Loading institutional data...
Loading institutional data...
Institutional accumulation: ownership increased +1.12% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $7.91 today, the market must believe free cash flow compounds 29.5%/yr for a decade (off $3M normalized FCF).
2-stage DCF · 0.04B shares · net debt -$2M
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$1M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~12.7% on $9M of debt.
Cash of $11M fully covers short-term debt of $0.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69.3M 100.0% | $101.5M 100.0% | $83.6M 100.0% | $72.8M 100.0% | $61.9M 100.0% | $62.2M 100.0% | $61.3M 100.0% | $63.4M 100.0% | $57.3M 100.0% | $53.3M 100.0% |
| Cost of Revenue | $57.6M 83.1% | $84.0M 82.8% | $74.9M 89.6% | $68.7M 94.4% | $64.4M 103.9% | $59.5M 95.6% | $58.5M 95.4% | $65.0M 102.5% | $53.6M 93.5% | $46.5M 87.3% |
| Cost of Products | — | — | — | — | — | — | — | — | $53.6M 93.5% | $46.5M 87.3% |
| Gross Profit | $11.7M 16.9% | $17.5M 17.2% | $8.7M 10.4% | $4.1M 5.6% | -$2.4M -3.9% | $2.7M 4.4% | $2.8M 4.6% | -$1.6M -2.5% | $3.7M 6.5% | $6.8M 12.7% |
| Research & Development | $0 0.0% | $19K 0.0% | $1.1M 1.3% | — | — | — | — | $5.6M 8.9% | $6.3M 11.0% | $5.8M 11.0% |
| Selling, General & Admin | $14.0M 20.3% | $14.1M 13.9% | $12.1M 14.5% | $15.6M 21.5% | $15.3M 24.8% | $16.2M 26.0% | $21.0M 34.3% | $23.1M 36.4% | $23.3M 40.7% | $21.1M 39.6% |
| Operating Income | -$4.7M -6.8% | $608K 0.6% | -$6.7M -8.0% | -$16.8M -23.0% | -$30.3M -49.0% | -$28.4M -45.7% | -$34.5M -56.3% | -$32.4M -51.2% | -$25.9M -45.2% | -$20.2M -37.9% |
| Interest Expense | $1.1M 1.6% | $1.3M 1.2% | $2.3M 2.8% | $1.9M 2.7% | $2.4M 3.8% | $1.9M 3.0% | $25K 0.0% | — | — | — |
| Interest & Investment Income | — | — | $211K 0.3% | $33K 0.0% | $22K 0.0% | $238K 0.4% | $392K 0.6% | — | — | — |
| Other Income (Expense), net | -$623K -0.9% | -$1.1M -1.1% | -$1.8M -2.1% | -$1.9M -2.6% | -$2.3M -3.8% | -$2.5M -4.0% | $397K 0.6% | $313K 0.5% | $2K 0.0% | — |
| Pretax Income | -$5.3M -7.7% | -$480K -0.5% | -$8.4M -10.1% | — | — | — | — | — | -$25.9M -45.2% | -$19.4M -36.4% |
| Income Tax Expense | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $405K 0.8% |
| Net Income | -$5.3M -7.7% | -$480K -0.5% | -$8.4M -10.1% | -$18.7M -25.7% | -$32.7M -52.8% | -$30.9M -49.7% | -$34.1M -55.7% | -$32.1M -50.7% | -$25.9M -45.2% | -$19.8M -37.2% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | — | — | $-0.51 | $-0.39 |
| EPS (Diluted) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | — | — | $-0.51 | $-0.39 |
| Weighted Avg Shares (Basic) | 36.0M | 31.1M | 23.3M | 14.3M | 8.5M | 75.6M | — | — | 51.1M | 50.7M |
| Weighted Avg Shares (Diluted) | 36.0M | 31.1M | 23.3M | 14.3M | 8.5M | 75.6M | — | — | 51.1M | 50.7M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| RMTI | $307M | — | — | 4.4× | -31.8% | 16.9% | -7.7% | -14.4% | -11.6% | -3.5× | 42 |
Peers = companies sharing RMTI's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
No standout strengths flagged.
Where each multiple sits in its own 14-yr range · 4th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 27.4× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 102.5 | 95.4 | 95.6 | 103.9 | 94.4 | 89.6 | 82.8 | 83.1 |
| Gross Profit | -2.5 | 4.6 | 4.4 | -3.9 | 5.6 | 10.4 | 17.2 | 16.9 |
| R&D | 8.9 | — | — | — | — | 1.3 | 0.0 | 0.0 |
| SG&A | 36.4 | 34.3 | 26.0 | 24.8 | 21.5 | 14.5 | 13.9 | 20.3 |
| Operating Income | -51.2 | -56.3 | -45.7 | -49.0 | -23.0 | -8.0 | 0.6 | -6.8 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | -50.7 | -55.7 | -49.7 | -52.8 | -25.7 | -10.1 | -0.5 | -7.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on RMTI: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.